Enterprise Value
5.002B
Cash
599.9M
Avg Qtr Burn
-44.21M
Short % of Float
12.15%
Insider Ownership
0.66%
Institutional Own.
-
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IZERVAY™ (avacincaptad pegol intravitreal solution) Details Age-related macular degeneration, Eye disease , Geographic atrophy | Approved Quarterly sales | |
Zimura (avacincaptad pegol) Details Macular degeneration, Inflammatory disease, Autoimmune disease | Phase 2b Update |